Does a post-merger biotech company need a fractional CRO in 2027?

Direct Answer

A post-merger biotech in 2027 faces a unique window: the combined entity has two sales cultures, two compensation plans, and two customer bases that must be rationalized quickly. A fractional CRO brings the specific expertise to design a single go-to-market structure, align incentive plans, and integrate revenue operations — without the long-term commitment of a full-time hire. The cost range reflects whether you need 10 days per month (lower end) or near-full-time presence (upper end), and whether you offer a small equity grant to reduce cash outlay.

The post-merger biotech revenue challenge

When two biotech companies merge, the revenue function is rarely the first thing integrated. Legal, R&D, and manufacturing take priority. But by month three, the sales teams are working from two different playbooks, two different CRM instances, and two different commission structures. This is where a fractional CRO becomes a practical solution — you need someone who has done this before, but you cannot justify a permanent executive salary until the combined revenue reaches a stable run rate.

The biotech context matters. Sales cycles in biotech are long, heavily regulated, and often involve multiple stakeholders across clinical, procurement, and executive levels. A fractional CRO who has operated in life sciences understands the compliance requirements around data privacy, off-label communication restrictions, and the need for medical affairs alignment. A generalist fractional CRO from SaaS may struggle with these nuances.

What a fractional CRO actually does in this scenario

The work breaks down into four phases. First, diagnose the current state: audit both CRM systems, interview the top performers from each legacy team, and identify where pipeline is duplicated or missing. Second, design the unified revenue model: single territory plan, single comp plan, single sales process. Third, lead the transition: manage the change, handle the difficult conversations about who gets which accounts, and set new quotas. Fourth, stabilize and handoff: once the combined team is running on one system with one rhythm, the fractional CRO either reduces to an advisory role or exits.

When a fractional CRO is the wrong answer

There are three situations where you should not hire a fractional CRO for your post-merger biotech. First, if you have not yet appointed a single VP of Sales or Head of Revenue for the combined entity. A fractional CRO works best when there is a clear internal counterpart who owns the day-to-day. If you have no revenue leader at all, you may need a full-time CRO first.

Second, if the merger is primarily about cost-cutting and you plan to lay off most of the combined sales force. In that case, you need a restructuring consultant or an interim VP of Sales, not a fractional CRO focused on growth. Third, if your board expects a full-time executive presence for investor confidence. Some boards will not accept a fractional leader in a key role, especially for a public biotech or one preparing for a fundraise.

How to evaluate a fractional CRO for biotech

You need to vet differently than you would for a SaaS company. Ask for specific examples of post-merger integration in regulated industries. A strong candidate will describe how they handled comp plan harmonization when one company paid high base and low commission and the other paid low base and high commission. They should also explain how they managed CRM migration without losing pipeline data.

Check for experience with the specific buyer types in your market — hospital systems, group purchasing organizations, distributors, or direct to clinics. Each has a different sales motion. A fractional CRO who only knows enterprise SaaS will miss the nuances of GPO contracts and compliance requirements.

Expect a diagnostic phase of two to four weeks before they commit to a plan. Any fractional CRO who offers a fixed solution on day one without understanding your specific legacy systems is selling a template, not a custom integration.

The cost and commitment tradeoffs

The monthly fee for a fractional CRO in biotech ranges from $8,000 for a light advisory role (two days per week, no travel) to $25,000 for a near-full-time engagement (four days per week, on-site visits, direct management of sales team). Equity is common but not universal — some fractional CROs will accept 0.25% to 0.5% of the combined entity in exchange for a lower cash rate. This works well for early-stage biotechs where cash is tight and the upside is real.

The typical engagement runs six to nine months. Shorter than three months is rarely enough to complete the integration and see results. Longer than twelve months suggests the integration is stalled or the fractional CRO is being used as a permanent crutch, which is not the intended model.

FAQ

What is the minimum company size for a fractional CRO to make sense? Any post-merger biotech with at least $2 million in combined revenue and a sales team of five or more can benefit. Below that, the founder or CEO should handle the integration directly.

Will a fractional CRO report to the board? Typically no. They report to the CEO or the designated revenue leader. If the board requires direct access, you can include them in quarterly board meetings as an attendee, not a member.

How do we handle the two legacy CRM systems? The fractional CRO will lead the migration to a single instance of Salesforce, HubSpot, or another platform. They will not do the technical work themselves but will oversee the project and ensure data integrity.

Can a fractional CRO fire underperforming salespeople? Yes, if that authority is explicitly given in the engagement letter. Most fractional CROs will recommend terminations but prefer to have the CEO or VP of Sales execute them to maintain internal authority.

What happens if the merger fails or the combined entity is sold? The engagement typically includes a 30-day termination clause. The fractional CRO will hand over all documentation and transition notes. No long-term liability.

Is a fractional CRO a replacement for a VP of Sales? No. A fractional CRO focuses on strategy, structure, and integration. The VP of Sales owns day-to-day execution. They are complementary roles.

Sources

• Pavilion — Community for revenue leaders
• RevOps Co-op — Revenue operations best practices
• Harvard Business Review — Mergers and integration strategy
• First Round Review — Sales leadership and scaling
• SaaStr — Go-to-market advice for founders
• LinkedIn — Professional network for vetting fractional executives

People also search for: fractional cro · hire a fractional cro · fractional cro near me · fractional cro cost